CLIENT LOGIN
Investors2021-05-13T14:13:15-07:00
FOR INVESTORS

News, events, and reports.


Investor Presentations

Recent Healthcare Conferences

View our presentations

Scientific Evidence

MammaPrint and BluePrint Utility

View our Landmark Trials

Reach out to our investor relations department.

Contact Us

Recent Events & News

Healthcare Conferences

Agendia’s leadership team presents at healthcare conferences globally to share updates on the company and our vision for how we fit into the breast cancer treatment space

View Presentations Here

MINDACT Update

Long term follow up data for the EORTC’s landmark MINDACT trial were presented at major conferences in 2020 and confirm MammaPrint’s utility for women with breast cancer

View Data Here

NBRST Update

Five-year follow up data for Agendia’s prospective NBRST trial were presented at SABCS 2020 and confirm the utility of our tests for pre-operative treatment planning

View Data Here

SABCS 2020

Agendia will present new data from ongoing clinical research evaluating the MammaPrint and BluePrint genomic tests at the upcoming […]

View More Information
Two women reading about genomic breast cancer results

Latest News

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

Read The Article
I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

View The Documentary

Investor News

1201, 2022

Agendia to Provide First Digital MammaPrint Capability to Brazil

January 12th, 2022|

AI solution will expand Agendia’s testing platform in the Brazilian breast cancer market Digital MammaPrint offers fast turnaround time to molecular diagnostics, delivering actionable information to physicians treating patients with breast cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 12, 2022 – Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced that it is offering early access to its Digital MammaPrint platform for patients with breast cancer in Brazil, expanding the company’s offerings in the country with the goal of bringing essential information from cancer testing to the larger global breast cancer community. Brazil is the first country to have samples analyzed by Digital MammaPrint, allowing physicians and their patients to benefit from Read More

1001, 2022

Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care

January 10th, 2022|

Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing, to bring improved insights to patients with breast cancer globally IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 10, 2022 – Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc. (NASDAQ: ILMN), to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina’s approach to IVD partnerships in oncology. Agendia joins Illumina’s growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection, and other applications. Illumina and Agendia Read More

601, 2022

Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors, Strengthening Advisory Group to Support Company Momentum

January 6th, 2022|

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 6, 2022 – Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced the appointment of healthcare industry veterans Suja Chandrasekaran, MS and Scott Mendel, MBA to the Company’s Board of Directors. “We are pleased to be expanding Agendia’s Board of Directors with the appointment of two accomplished industry executives,” said Mark Straley, Chief Executive Officer of Agendia. “With combined decades of leadership and results-driven performance, Suja and Scott will provide Agendia with invaluable guidance, informed by extensive executive experience. As we continue to deliver on our goal to provide crucial genomic information to physicians and their patients to improve care, we look forward to tapping into Read More

1012, 2021

Agendia Spotlight Poster at SABCS 2021 Confirms Utility of BluePrint as Biomarker Subtyping Test to Guide Neoadjuvant Chemotherapy Decisions

December 10th, 2021|

Additional research from the real-world FLEX Registry focuses on age effect and lymph node status for patients with breast cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 10, 2021 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced that it will present a spotlight poster at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021) which confirms the utility of BluePrint® in guiding neoadjuvant treatment decisions. The spotlight presentation, resulting from a research collaboration between Agendia and the Netherlands Cancer Institute and titled Effect of pertuzumab plus neoadjuvant trastuzumab-based chemotherapy in early-stage HER2-positive breast cancer according to BluePrint molecularly defined breast cancer subtypes [PD15-07], evaluates the BluePrint 80-gene molecular subtyping test for predicting response to Read More

912, 2021

Analysis Presented at SABCS 2021 Confirms MammaPrint and BluePrint Predict Outcomes Following Neoadjuvant Chemotherapy

December 9th, 2021|

Data signal importance of serial genomic testing in order to appropriately adjust breast cancer treatment plans IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2021 – Agendia, Inc., a world leader in precision oncology for breast cancer, today shared data demonstrating the ability of MammaPrint® and BluePrint® to predict patient outcomes following neoadjuvant chemotherapy (NAC) at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021). The poster, titled MammaPrint and BluePrint are prognostic of outcome following neoadjuvant chemotherapy, presents findings that indicate MammaPrint and BluePrint accurately correlated with chemosensitivity and outcomes in NAC-treated patients. The research was conducted in collaboration with Cedars-Sinai Medical Center. Notably, approximately 1 in 4 tumors which were MammaPrint High Risk (Luminal B) prior to Read More

912, 2021

Agendia Presents Data at SABCS 2021 Showing MammaPrint and BluePrint More Robustly Identify Genomic Differences in HR+ HER2- Breast Cancers in Black and White Women Beyond Clinical Factors

December 9th, 2021|

ER+ tumors reclassified by BluePrint as Basal-type occur at a higher frequency in Black women compared to White women Understanding tumor biological differences via MammaPrint and BluePrint and will drive better, more personalized care   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2021 – Agendia, Inc., a world leader in precision oncology for breast cancer, today presented data from a research collaboration with Vanderbilt University Medical Center demonstrating the capability of MammaPrint® and BluePrint® to identify differences in recurrence risk and tumor classification amongst different racial groups at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021). The presentation, titled MammaPrint and BluePrint identify genomic differences in HR+ HER2- breast cancers from young Black and White women, highlights Read More

Go to Top